# A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

> **NCT05171049** · PHASE3 · TERMINATED · sponsor: **Anthos Therapeutics, Inc.** · enrollment: 1150 (actual)

## Conditions studied

- Venous Thromboembolism
- Deep Venous Thrombosis
- Pulmonary Embolism

## Interventions

- **BIOLOGICAL:** Abelacimab
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT05171049
- **Lead sponsor:** Anthos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-05
- **Primary completion:** 2026-02-04
- **Final completion:** 2026-02-04
- **Target enrollment:** 1150 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171049, "A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05171049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*